Trevena, Inc. - רווח נקי למניה (EPS TTM) TRVN

Trevena, Inc. (TRVN) develops innovative analgesics, offering Olinvyk as a safe alternative to opioids for intensive care units. The business model relies on outsourcing production and trials to minimize capital expenditures. However, sluggish demand for the drug has led to stagnation and strict austerity measures. The 12-month EPS trend captures profitability, where -55.96 indicates the value of this parameter.

The metric's calculation formula directly reflects the difference between operating revenue and total expenses. This indicator measures net income allocated per share over a trailing twelve-month period, assessing the actual return on capital. At Trevena, Inc. (TRVN), high fixed costs coupled with scaled-back commercial programs suppress this result. The current liquidity deficit blocks profit growth. The TTM earnings per share trend confirms business stagnation.